Vanderbilt University: Potential Prostate Cancer Biomarkers
September 21, 2019
September 21, 2019
NASHVILLE, Tennessee, Sept. 21 [TNSmedicalresearch] -- Vanderbilt University issued the following news:
Biomarkers for screening and early detection of prostate cancer -- the most common and second deadliest cancer in U.S. males -- are limited. PSA (prostate-specific antigen) is widely used but is controversial because of its unclear benefit and contribution to prostate cancer overdiagnosis.
Wei Zheng, MD, PhD, and colleagues used genetic tools to search for association . . .
Biomarkers for screening and early detection of prostate cancer -- the most common and second deadliest cancer in U.S. males -- are limited. PSA (prostate-specific antigen) is widely used but is controversial because of its unclear benefit and contribution to prostate cancer overdiagnosis.
Wei Zheng, MD, PhD, and colleagues used genetic tools to search for association . . .